Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

835 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation".
Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz J, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. Wallentin L, et al. Circulation. 2014 Jan 14;129(2):e21-2. doi: 10.1161/CIRCULATIONAHA.113.005709. Circulation. 2014. PMID: 24421367 No abstract available.
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
Wallentin L, Bergstrand L, Dellborg M, Fellenius C, Granger CB, Lindahl B, Lins LE, Nilsson T, Pehrsson K, Siegbahn A, Swahn E. Wallentin L, et al. Eur Heart J. 2003 May;24(10):897-908. doi: 10.1016/s0195-668x(03)00006-x. Eur Heart J. 2003. PMID: 12714021 Clinical Trial.
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
Dubois CL, Belmans A, Granger CB, Armstrong PW, Wallentin L, Fioretti PM, López-Sendón JL, Verheugt FW, Meyer J, Van de Werf F; ASSENT-3 Investigators. Dubois CL, et al. Among authors: wallentin l. J Am Coll Cardiol. 2003 Oct 1;42(7):1178-85. doi: 10.1016/s0735-1097(03)00917-3. J Am Coll Cardiol. 2003. PMID: 14522476 Free article. Clinical Trial.
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
Sinnaeve PR, Alexander JH, Bogaerts K, Belmans A, Wallentin L, Armstrong P, Adgey JA, Tendera M, Diaz R, Soares-Piegas L, Vahanian A, Granger CB, Van De Werf FJ. Sinnaeve PR, et al. Among authors: wallentin l. Am Heart J. 2004 Jun;147(6):993-8. doi: 10.1016/j.ahj.2003.12.028. Am Heart J. 2004. PMID: 15199346 Clinical Trial.
Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA).
Stenestrand U, Lindbäck J, Wallentin L; RIKS-HIA Registry. Stenestrand U, et al. Among authors: wallentin l. Circulation. 2005 Nov 22;112(21):3225-31. doi: 10.1161/CIRCULATIONAHA.105.552984. Circulation. 2005. PMID: 16301355
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Lagerqvist B, Husted S, Kontny F, Ståhle E, Swahn E, Wallentin L; Fast Revascularisation during InStability in Coronary artery disease (FRISC-II) Investigators. Lagerqvist B, et al. Among authors: wallentin l. Lancet. 2006 Sep 16;368(9540):998-1004. doi: 10.1016/S0140-6736(06)69416-6. Lancet. 2006. PMID: 16980115 Clinical Trial.
Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS.
Sinnaeve PR, Huang Y, Bogaerts K, Vahanian A, Adgey J, Armstrong PW, Wallentin L, Van de Werf FJ, Granger CB; ASSENT-3 and ASSENT-3 PLUS investigators. Sinnaeve PR, et al. Among authors: wallentin l. Am Heart J. 2006 Oct;152(4):684.e1-9. doi: 10.1016/j.ahj.2006.07.005. Am Heart J. 2006. PMID: 16996833
Anticoagulants in heart disease: current status and perspectives.
De Caterina R, Husted S, Wallentin L, Agnelli G, Bachmann F, Baigent C, Jespersen J, Kristensen SD, Montalescot G, Siegbahn A, Verheugt FW, Weitz J. De Caterina R, et al. Among authors: wallentin l. Eur Heart J. 2007 Apr;28(7):880-913. doi: 10.1093/eurheartj/ehl492. Epub 2007 Apr 10. Eur Heart J. 2007. PMID: 17426080 Free article. No abstract available.
835 results